- Home
- XTKG vs BTAI Comparison
XTKG vs BTAI Comparison
Compare XTKG & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- BTAI
- Stock Information
- Founded
- XTKG 1997
- BTAI 2017
- Country
- XTKG Singapore
- BTAI United States
- Employees
- XTKG 178
- BTAI N/A
- Industry
- XTKG
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- BTAI Health Care
- Exchange
- XTKG NYSE
- BTAI Nasdaq
- Market Cap
- XTKG 13.7M
- BTAI 18.1M
- IPO Year
- XTKG 2019
- BTAI 2018
- Fundamental
- Price
- XTKG $0.99
- BTAI $0.34
- Analyst Decision
- XTKG
- BTAI Buy
- Analyst Count
- XTKG 0
- BTAI 4
- Target Price
- XTKG N/A
- BTAI $2.81
- AVG Volume (30 Days)
- XTKG 205.7K
- BTAI 1.3M
- Earning Date
- XTKG 11-27-2024
- BTAI 03-11-2025
- Dividend Yield
- XTKG N/A
- BTAI N/A
- EPS Growth
- XTKG N/A
- BTAI N/A
- EPS
- XTKG N/A
- BTAI N/A
- Revenue
- XTKG $15,234,138.00
- BTAI $2,276,000.00
- Revenue This Year
- XTKG N/A
- BTAI $131.23
- Revenue Next Year
- XTKG N/A
- BTAI $45.79
- P/E Ratio
- XTKG N/A
- BTAI N/A
- Revenue Growth
- XTKG 51.59
- BTAI 83.25
- 52 Week Low
- XTKG $0.08
- BTAI $0.30
- 52 Week High
- XTKG $2.14
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- XTKG 49.71
- BTAI 42.14
- Support Level
- XTKG $0.90
- BTAI $0.33
- Resistance Level
- XTKG $1.38
- BTAI $0.39
- Average True Range (ATR)
- XTKG 0.17
- BTAI 0.06
- MACD
- XTKG -0.02
- BTAI -0.00
- Stochastic Oscillator
- XTKG 23.92
- BTAI 9.27
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.